Personalised randomised controlled trial designs – a new paradigm to define optimal treatments for carbapenem-resistant infections
Antimicrobial resistance is impacting treatment decisions for, and patient outcomes from, bacterial infections worldwide, with particular threats from infections with carbapenem-resistant Enterobacteriaceae, Acinetobacter baumanii, or Pseudomonas aeruginosa. Numerous areas of clinical uncertainty su...
Main Authors: | Walker, AS, White, IR, Turner, R, Yang, HL, Wen, YT, White, N, Sharland, M, Thwaites, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2021
|
Similar Items
-
The Personalised Randomised Controlled Trial (PRACTical): evaluation of a new trial design
by: Lee, KM, et al.
Published: (2023) -
The use of polymyxins to treat carbapenem resistant infections in neonates and children
by: Thomas, R, et al.
Published: (2018) -
The road to personalised medicine in psoriatic arthritis
by: White, JPE, et al.
Published: (2021) -
Determining sample size in a personalized randomized controlled (PRACTical) trial
by: Turner, RM, et al.
Published: (2024) -
Planning a method for covariate adjustment in individually-randomised trials: a practical guide
by: Morris, TP, et al.
Published: (2022)